EcoR1's Oleg Nodelman Buys $17.2M of AnaptysBio Stock in Three-Day Open-Market Run
ANAB has more than doubled off its 52-week low of $22.063.
Summary
Director and 10% owner Oleg Nodelman (EcoR1 Capital) bought 374,580 AnaptysBio shares for $17.2 million in open-market trades on November 16-18, raising the stake to 8.25 million shares.
Key Events · Ownership and Investor Activity · ANAB
-
Insider Buys $17.2M in Open Market
EcoR1 Capital and Oleg Nodelman acquired 374,580 shares across three transactions from 2026-11-16 to 2026-11-18 at prices between $45.66 and $46.54, totaling $17,224,592.78.
-
Stake Rises to 8.25 Million Shares
Post-transaction holdings reached 8,254,674 shares, with the Qualified Fund holding 7,642,937 of them after the final purchase.
-
Buying Into Delaware Litigation Risk
The purchases came after shares dropped 8% on 2026-10-20 when the Delaware Chancery hearing over the dostarlimab contract dispute began; the ruling is still pending per the Q3 10-Q.
-
Fund Manager, Not Operating Executive
Nodelman is a director and 10% owner through EcoR1 Capital, so the purchase reflects a large holder's conviction rather than an operating officer's view.
Analysis · ANAB · Life Sciences
A director and 10% owner put $17.2 million of real money into the open market over three consecutive sessions, lifting the EcoR1-linked stake to 8.25 million shares. That is a large, unplanned purchase rather than an option exercise or grant, and it lands while AnaptysBio waits on a Delaware Chancery ruling over dostarlimab rights and after the stock fell 8% when that hearing began. Buying into that uncertainty is the strongest insider conviction signal the company has produced recently, though the buyer is a fund manager rather than an operating executive, so read it as a major holder defending and adding to its position rather than as management guidance.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANAB was trading at $47.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $22.06 to $72.36. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.